6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2010

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

 (Translation of registrant’s name into English)

48th Floor, Bank of China Tower

1 Garden Road

Central

Hong Kong S.A.R.

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                              Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o                                No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_______________.

Entry into a Material Definitive Agreement

On February 24, 2010, China Stem Cells (East) Company Limited (“CSC”), an indirect wholly-owned subsidiary of China Cord Blood Corporation (the “Company”), entered into a Securities Purchase Agreement (the “Agreement”) with Glorysun Holdings Group Limited (“Seller”).  Seller is the sole shareholder of Zanbao Company Ltd. (“Zanbao”), which in turn is the sole shareholder of Jinan Baoman Science & Technology Dev. Co. Ltd. (“Baoman”).  Baoman holds 24% of the equity interest of Shandong Province Jilu Stem Cell Engineering Co. Ltd. (“Jilu Stem Cell”).  Jilu Stem Cell manages the assets of Shandong Cord Blood Bank (“Shandong Cord Blood Bank”), which is the owner of the exclusive Cord Blood Banking License for the Shandong province in China.

Pursuant to the Agreement, CSC will acquire 83% of the share equity of Zanbao from Seller, resulting in CSC becoming the indirect beneficial owner of an effective interest of 19.92% of Jilu Stem Cell for an aggregate purchase price of HK$159,360,000.  The purchase price is payable in two installments, HK$80 million within 10 business days after entering into the Agreement and HK$79.4 million within 30 days after the date of the Agreement.  In addition, each of Shandong Yinfeng Investment Group Co. Ltd., the major shareholder of Jilu Stem Cell, and Seller has guaranteed that the dividend income attributable to CSC in calendar year 2010, based on an effective interest of 19.92% will be not less than approximately RMB7.07 million (approximately US$1.04 million) and will make up any shortfall in the actual profit of Jilu Stem Cell and the guaranteed amount. The dividend will be distributed from Jilu Stem Cell. CSC is also entitled to a right of first refusal if any shareholders of Jilu Stem Cell decide to dispose or transfer their equity interest in Jilu Stem Cell in the future.

The Seller makes customary representations and warranties in the Agreement.  The closing of the transaction is subject to customary closing conditions.

Other Events

On February 24, 2010, China Cord Blood Corporation (the “Company”) issued a press release announcing the entry into the Agreement. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.	Description
99.1	Press Release, dated February 24, 2010

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CHINA CORD BLOOD CORPORATION
	By:	/s/ Albert Chen
	Name:	Albert Chen
	Title:	Chief Financial Officer
Dated: February 24, 2010

EX-99.1

China Cord Blood Corporation Acquires Stake in

Shandong Cord Blood Bank

- Acquisition Represents Strategic Entry into Shandong Province and

Geographic Expansion for Cord Blood Services -

- Conference Call is Scheduled at 8:00 am ET / 9:00 pm HKT on February 25, 2010 - -

HONG KONG, February 24, 2010 -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's first and largest cord blood bank operator in terms of geographic coverage, today announced that as part of its nationwide expansion strategy, it has entered into an agreement to acquire an effective 19.92% equity interest in Shandong Cord Blood Bank (“SCBB”) for US$20.5 million (equivalent to HK$159.36 million) in an all-cash transaction.  The Company intends to use its available cash to fund the acquisition.  For the year ended December 31, 2010, CCBC’s equity interest in SCBB is expected to yield dividend income of US$1.04 million (approximately to RMB7.07 million).

SCBB holds the exclusive license to provide cord blood services to eastern China’s affluent Shandong Province.  Upon the completion of the transaction, CCBC will own an indirect 19.92% interest in SCBB and is entitled to the right of first refusal on future transfers of SCBB equity interest, allowing it to expand its position in the future.

In China, the government enforces a one-license-per-region policy for operating cord blood banks, and so far it has only granted six licenses nationwide.  Of those six, the Company holds two (to operate in Beijing and Guangdong Province) and this acquisition grants access to the third.  No other company holds more than one of the remaining licenses.

Ms. Tina Zheng, Chairperson and CEO, said, “We are very pleased about the SCBB acquisition, which marks an important milestone in our Company’s development of a nationwide business.  We are also very excited about the prospects of China’s cord blood storage industry, given its unique business environment and the size of its addressable market. This strategic expansion will increase CCBC’s competitive advantage by enlarging the size of our potential market to three provinces with over 2.1 million new births per annum, representing growth of 1.1 million new births per annum.  This, in turn, is expected to further drive CCBC’s business growth and reinforce our dominance in China.  We will leverage our in-depth market knowledge, hospital resources and marketing experience from our Beijing and Guangdong operations to enhance the Shandong operation.”

1

Ms. Zheng continued, “Through this acquisition, we will demonstrate to investors our distinct ability to deliver results.  We believe a successful consolidation will place us in a strategically advantageous position and pave the way for future corporate developments and strategic alliances within China.”

Audio Webcast

The Company will hold an audio webcast at 8:00 a.m. US ET / 9:00 p.m. HKT on Thursday, February 25, 2010 to give a brief overview of the Company’s developments on the acquisition, followed by a question and answer session.

Interested parties may access the audio webcast by following the below link: http://phx.corporate-ir.net/playerlink.zhtml?c=206671&s=wm&e=2764714.  A replay of the webcast will be accessible two hours after the presentation and will remain available for a year at the same URL link above.

To participate in the question and answer session, please dial 1-718-354-1231 or 1-866-519-4004 for US callers or +852 2475-0994 for Hong Kong callers, conference access id: 58763462.  Please dial-in 10 minutes before the question and answer session begins to ensure proper connection.

*    *    *

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong).  Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information about China Cord Blood Corporation, please visit: http://www.chinacordbloodcorp.com.

2

Forward-looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

China Cord Blood Corporation

Ms. Joe-ling Law

Phone: +852-3605-8180

Email: ir@chinacordbloodcorp.com

ICR, Inc.

In the United States:

Ashley M. Ammon : Phone: +1-646-277-1227

Christine Duan : Phone: +1-203-682-8200

In China:

Wei-Jung Yang : Phone: +86-10-6599-7968

3